Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Etilefrine is a sympathomimetic small molecule drug used primarily as an antihypotensive agent to treat orthostatic hypotension and other forms of low blood pressure. It acts as an adrenergic agonist, with primary activity at the α1-adrenergic and β1-adrenergic receptors, leading to increased cardiac output, stroke volume, venous return, and blood pressure. Etilefrine also has some activity at β2-adrenergic receptors but with much lower affinity. Its mechanism involves direct stimulation of these adrenergic receptors in the sympathetic nervous system, resulting in vasoconstriction and cardiac stimulation. The drug is rapidly absorbed orally (bioavailability ~50%), widely distributed (including heart and vessels), metabolized mainly by conjugation in the liver (glucuronidation/sulfation), and excreted mostly via urine[1][2][5][6]. It is available for oral or injectable administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on etilefrine.